| 王首杰,屈 延,秦怀洲,蔡 青,冯小英.依达拉奉联合醒脑静治疗急性脑出血[J].,2017,17(33):6491-6494 |
| 依达拉奉联合醒脑静治疗急性脑出血 |
| Edaravone combined with Xingnaojing Injection in the Treatment of Acute Cerebral Hemorrhage |
| 投稿时间：2017-05-08 修订日期：2017-06-03 |
| DOI：10.13241/j.cnki.pmb.2017.33.020 |
| 中文关键词: 急性脑出血 依达拉奉 醒脑静 生化指标 |
| 英文关键词: Acute cerebral hemorrhage edaravone Xingnaojing injection biochemical index |
| 基金项目: |
|
| 摘要点击次数: 73 |
| 全文下载次数: 88 |
| 中文摘要: |
| 摘要 目的：探讨依达拉奉联合醒脑静治疗急性脑出血（Acute cerebral hemorrhage，ACH）对患者炎性因子、血管内皮功能及氧化应激水平的影响。方法：回顾性分析96例ACH患者，依据治疗方法将其分为对照组（n=46）和观察组（n=50）。对照组患者在常规治疗基础上给予依达拉奉治疗，观察组患者在对照组的基础上给予醒脑静治疗，两组患者均连续治疗14 d。比较两组的总有效率，NIHSS评分以及治疗前后的炎性因子（TNF-α、IL-6和hs-CRP）、血管内皮功能（NO和ET-1）及氧化应激（SOD和MDA）水平。结果：与对照组相比，观察组的总有效率显著升高，治疗后的NIHSS评分显著下降，差异有统计学意义（P<0.05）；与同组内治疗前相比治疗后两组患者的TNF-α、IL-6、hs-CRP、NO、ET-1和MDA水平均显著下降，且治疗后观察组各指标水平显著低于对照组治疗后（P<0.05）；两组的SOD较同组内治疗前均显著升高，且观察组水平显著高于对照组（P<0.05）。结论：依达拉奉联合醒脑静治疗ACH，可有效改善患者的NIHSS评分、降低患者的炎性因子水平，改善血管内皮功能及氧化应激水平，临床疗效显著，具有一定的临床价值，值得推广。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the influence of edaravone combined with Xingnaojing injection on the levels of inflammatory factors, vascular endothelial function and oxidative stress in patients with acute cerebral hemorrhage (ACH). Methods: 96 cases of ACh patients were analyzed retrospectively, they were divided into control group (n=46) and observation group (n=50), according to the treat- ment method. The control group was treated with edaravone treatment on the basis of routine treatment, patients in the observation group on the basis of the control group treated with Xingnaojing treatment, two patients were treated for 14 d. The total effective rate of the two groups, the NIHSS score after treatment, and the levels of inflammatory factors, and the inflammatory factors (TNF-α, IL-6 and hs-CRP), vascular endothelial function (NO and ET-1) and oxidative stress (SOD and MDA) levels were compared between the two groups before and after treatment. Results: The total effective rate of the observation group was significantly higher than that of the control group, and after treatment, the NIHSS score of the observation group was significantly lower than that of the control group. After treatment, The levels of TNF-α, IL-6, hs-CRP, NO, ET-1 and MDA in the two groups were significantly lower than those in the same group before treatment, and the observation group was significantly lower than the control group (P<0.05); SOD in the two groups was significantly higher than that in the same group before treatment, and the observation group was significantly higher than the control group(P<0.05). Conclusion: Edaravone combined with Xingnaojing Injection in the treatment of ACh, can effectively improve the pa- tients' NIHSS score, effectively reduce the level of inflammatory factors in patients, improve endothelial function and oxidative stress in vascular, clinical curative effect is remarkable, has certain clinical value, worthy of promotion. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
